OUR FOUNDATION

Hope. Cures. Awareness. Advocacy. Access. Support.

RTW Charitable Foundation works to improve opportunities for all people to live healthier, longer lives and was created at the intersection of scientific advancements and humanitarian efforts.

accepting-applications-icon.png

Grant Applications

Foundation Mission

Identify unmet needs and impact research and patients directly.

The RTW Charitable Foundation is proud to support pioneers who are breaking new ground in the fight against diseases that may not represent compelling commercial opportunities, but do result in significant human suffering.

The Foundation is able to provide capital, manpower, and logistical support to help scientists push such projects forward. In addition, the Foundation aims to assist in advocacy, disease awareness and directly support patients and their families.

Grant Progams

The RTW Charitable Foundation supports transformative rare disease research, patient support, education and policy that measurably impacts patients.

2021

Priority Focus Area

For Unmet Needs

Pediatric rare diseases

Rare diseases in CNS & Cardiovascular System

COVID-related support

Research

Fund rare disease research

Patient Support Programs

Assist rare disease patients in getting access to experimental and approved therapies

Education & Awareness

Educate and raise awareness of rare diseases

Humanitarian

Fund local and global relief efforts and humanitarian causes

Our Most Recent Work

COVID-19 Relief Effort

This winter RTW Charitable Foundation has completed its first grant cycle, totaling $1 million of gifts across 12 organizations fighting COVID-19, and the pandemic’s impact on New Yorkers. To learn more about grantees and their work please follows us on social media:

What's New

Investing in Human Lives

The RTW Charitable Foundation represents an extension of our investment firm mission.  Our research process helps us identify important causes of human suffering, and introduces us to individuals and organizations trying to make a difference.

To our research grant recipients, we can offer not only financial support, but also guidance gleaned from our experience in drug development and company building.

Beyond research, the Foundation can offer support to humanitarian causes, initiatives that raise disease awareness and programs with a direct patient impact.

Fueling Innovation
And Beyond

While the Foundation will support research in more common disease areas and humanitarian causes, the Foundation has an initial focus of supporting rare disease research and education. Drug development research for rare diseases often lacks the funding needed to learn if a treatment is effective and safe.  In addition, some conditions are so rare that no profit model exists to bring such treatments to market.  The Foundation believes that the lack of profit should not be a deterrent to promising treatments that can impact the lives of many living with rare diseases. Priority areas will be proposed annually and may include specific rare disease areas of focus.
2021
Priority Focus Areas
For Unmet Needs
Pediatric rare diseases
Rare diseases in CNS & Cardiovascular System
COVID-related support

Valuing What Matters

The RTW Foundation is specifically directed to prioritize benefits to patients over financial reward. Our dedicated staff know that only part of the struggle to relieve patients’ suffering takes place in laboratories. Many of the diseases we target affect not only patients but their families as well, often in devastating ways. We aid these families by:

Providing

information and coordinating assistance

Advocating

for patients whose voices might not otherwise be heard

Raising

public awareness

RTW Charitable Foundation Leadership Team

Foundation Leadership

Deborah Slipetz

Vice President
Deborah Slipetz

Vice President

Deborah serves as Vice President of RTW Charitable Foundation and is responsible for leading the foundation and executing on its strategic mission to improve opportunities for all people to live healthier, longer lives.

Prior to joining RTWCF, Deborah Slipetz was at Merck and has 30 years of experience as a drug hunter scientist and executive leader in the pharmaceutical industry. She was part of the team that invented SingulairTM for asthma and has brought an additional 25 drug candidates into clinical trials. Deborah has broad depth and breadth of experience in drug discovery across multiple therapeutic areas. She recently served as Executive Director In-Vivo Pharmacology responsible for cardiovascular, diabetes, neuroscience, infectious diseases, respiratory, immunology and oncology therapeutic areas. Her core biology expertise lies within the respiratory and immunology area, where she held the position of therapeutic area lead.

Deborah most recently co-founded and served as the executive director of imagine@Merck, a transformative innovation engine that attracts thinkers and doers who seek to challenge the status quo by providing the framework to unleash and amplify their ingenuity to amplify change. This business unit served as a platform for employees to communicate and collaborate to drive change and identify solutions to pressing issues not only in drug development, but enterprise-wide. Her team was recognized by “Fast Company” in 2020 as one of the most “Innovative Teams”.

Deborah has a B.Sc. in cell and molecular biology, a M.Sc. in molecular genetics and a Ph.D. in pharmacology, all from McGill University, Montreal, Canada.

“I am honored and privileged to have the opportunity to work for the RTW Charitable Foundation. I have a unique opportunity to take my drug development experience and passion for innovation to focus on funding cutting edge research for rare diseases. I’m looking forward to hitting the ground running and serving the patients and communities who are at the heart of our mission at RTWCF.”

Nate Pelsma

Chief Operating Officer
Nate Pelsma

Chief Operating Officer

Nate Pelsma serves as the Chief Operating Officer for the RTW Foundation and the Managing Director for Communications and People for RTW Investments where he is responsible for the operations for the Foundation and leading communications and organizational development initiatives for RTW.

Prior to RTW, Nate has spent the past ten years as CFO and COO of JMG, a youth workforce development organization, and Teach Plus, a national teacher leadership organization. He taught for eight years as an adjunct professor of nonprofit management at the Carroll Graduate School of Management at Boston College. Prior to working at Teach Plus, he was an economist for Analysis Group. Nate started his nonprofit career at City Year where he managed national corporate partnerships. In addition, prior to joining the RTW team, Nate served as an independent board director for RTW’s private funds. Nate has an MBA from Boston College and a BA in English from the University of Kansas.

"These are the early days of a scientific renaissance, and at RTW we are investing in the companies that will have a profound impact on humanity. It is humbling and awe-inspiring to witness this transformation and to be that critical connection between entrepreneurs and patients."

Board of Directors

Roderick Wong, MD

Chairman
Roderick Wong, MD

Chairman

Roderick Wong, MD, serves as Managing Partner and Chief Investment Officer of RTW. Rod is responsible for managing the firm’s investments focused on innovative drug development. Prior to forming RTW, he was a Managing Director and sole Portfolio Manager for the Davidson Kempner Healthcare Funds. Before joining Davidson Kempner, Rod held various healthcare investment and research roles at Sigma Capital Partners and Cowen & Company.

Rod simultaneously received an MD from the University of Pennsylvania Medical School and an MBA from Harvard Business School, and graduated Phi Beta Kappa with a BS in Economics from Duke University.

Rod has a keen interest in educating the next generation of life science entrepreneurs. He regularly sits on a variety of corporate boards. In addition, he serves on the board of Penn Medicine, as an Adjunct Associate Professor of Finance at NYU Stern, and as Chairman of the RTW Charitable Foundation.

"We get to support some of the most inspiring doctors and entrepreneurs during the genomic age, when the secrets to disease are being unlocked in real time. It’s hard not to jump out of bed every morning excited to study science."

Stephanie A. Sirota

President
Stephanie A. Sirota

President

Stephanie A. Sirota, serves as a Partner and Chief Business Officer at RTW Investments, LP (“RTW”), where she is responsible for strategy and oversight of the firm’s business and corporate development as well as strategic partnerships with counterparties including banks, academic institutions, corporations, investors, and NGOs. She leads the business team on various types of domestic and cross-border transactions and is also responsible for shaping the firm’s governance policies underscoring impact and sustainability.

Stephanie has fifteen years of deal experience in financial services. Prior to joining RTW, she served as Director at Valhalla Capital Advisors, a macro and commodity investment manager. Stephanie also worked in the New York and London offices of Lehman Brothers, where she advised on various Merger & Acquisitions, IPOs, and capital market financing transactions with a focus on cross-border transactions for the firm’s global corporate clients.

Stephanie graduated with honors from Columbia University and also received a Master’s Degree from the Columbia Graduate School of Journalism. She has contributed to Fortune Magazine and ABCNews.com.

She serves as a director of RTW Venture Fund Ltd; President of the RTW Charitable Foundation; and Co-Chairman of Council of the New York Philharmonic.

"These are the early days of a scientific renaissance, and at RTW we are investing in the companies that will have a profound impact on humanity. It is humbling and awe-inspiring to witness this transformation and to be that critical connection between entrepreneurs and patients."

Marti Speranza Wong

President, Community Engagement

Access our Annual Results 2019 Presentation Recording

  • This field is for validation purposes and should be left unchanged.